内容紹介
Summary
Case 1:A 68—year—old woman was diagnosed with advanced HER2—positive breast cancer(T2N2aM0, cStage ⅢA). She was treated with 4 courses of preoperative chemotherapy with pertuzumab, trastuzumab, and docetaxel. She was diagnosed to have achieved partial remission(PR), and subsequently underwent a mastectomy and axillary dissection. Pathological examination revealed smaller than 1 mm(Grade 2b). Case 2:A 59—year—old woman was diagnosed with advanced HER2—positive breast cancer(T4bN1M0, cStage ⅢB). She was treated with 4 courses of preoperative chemotherapy with pertuzumab, trastuzumab, and docetaxel. She was diagnosed to have achieved PR(primary lesion:complete remission), and subsequently underwent a mastectomy and axillary dissection. Pathological examination revealed complete pathological response(Grade 3). Combination therapy with pertuzumab, trastuzumab, and docetaxel appears to be a useful preoperative chemotherapy regimen for locally advanced HER2—positive breast cancer.
要旨
症例1:68歳,女性。右乳房CDに径60 mmの腫瘤を触知し,針生検で浸潤性乳管癌,ER 3,PgR 0,HER2 3+,Ki—67 21.9%,全身検索でT2N2aM0,cStage ⅢAと診断された。pertuzumab,trastuzumab,docetaxelによる術前化学療法を4コース施行し,効果判定はPRであった。手術[Bt+Ax(Ⅱ)]を行い,病理結果はypT1mi,組織学的効果判定Grade 2bであった。症例2:59歳,女性。右乳房Cに径70 mmの腫瘤を触知し,針生検で浸潤性乳管癌,ER 0,PgR 0,HER2 3+,Ki—67 90%以上,全身検索でT4bN1M0,cStage ⅢBと診断された。症例1と同様に術前化学療法を4コース行い,効果判定はPR(原発巣はCR)であった。手術[Bt+Ax(Ⅱ)]を施行し,病理結果は原発巣・リンパ節ともにpCRで,組織学的効果判定Grade 3であった。NeoSphere試験において3剤併用術前化学療法はpCR率が45.8%と良好であり,HER2陽性局所進行乳癌に対する有望なレジメンと思われた。
目次
Case 1:A 68—year—old woman was diagnosed with advanced HER2—positive breast cancer(T2N2aM0, cStage ⅢA). She was treated with 4 courses of preoperative chemotherapy with pertuzumab, trastuzumab, and docetaxel. She was diagnosed to have achieved partial remission(PR), and subsequently underwent a mastectomy and axillary dissection. Pathological examination revealed smaller than 1 mm(Grade 2b). Case 2:A 59—year—old woman was diagnosed with advanced HER2—positive breast cancer(T4bN1M0, cStage ⅢB). She was treated with 4 courses of preoperative chemotherapy with pertuzumab, trastuzumab, and docetaxel. She was diagnosed to have achieved PR(primary lesion:complete remission), and subsequently underwent a mastectomy and axillary dissection. Pathological examination revealed complete pathological response(Grade 3). Combination therapy with pertuzumab, trastuzumab, and docetaxel appears to be a useful preoperative chemotherapy regimen for locally advanced HER2—positive breast cancer.
要旨
症例1:68歳,女性。右乳房CDに径60 mmの腫瘤を触知し,針生検で浸潤性乳管癌,ER 3,PgR 0,HER2 3+,Ki—67 21.9%,全身検索でT2N2aM0,cStage ⅢAと診断された。pertuzumab,trastuzumab,docetaxelによる術前化学療法を4コース施行し,効果判定はPRであった。手術[Bt+Ax(Ⅱ)]を行い,病理結果はypT1mi,組織学的効果判定Grade 2bであった。症例2:59歳,女性。右乳房Cに径70 mmの腫瘤を触知し,針生検で浸潤性乳管癌,ER 0,PgR 0,HER2 3+,Ki—67 90%以上,全身検索でT4bN1M0,cStage ⅢBと診断された。症例1と同様に術前化学療法を4コース行い,効果判定はPR(原発巣はCR)であった。手術[Bt+Ax(Ⅱ)]を施行し,病理結果は原発巣・リンパ節ともにpCRで,組織学的効果判定Grade 3であった。NeoSphere試験において3剤併用術前化学療法はpCR率が45.8%と良好であり,HER2陽性局所進行乳癌に対する有望なレジメンと思われた。